Weed on a GLP-1: Munchies, Edibles, Nausea, and Cannabis Use Data

Cannabis is not listed as a drug interaction on the Wegovy or Zepbound labels, but the combination raises three practical issues: THC can push appetite up while the GLP-1 pushes it down, edibles absorb through a gut the GLP-1 is slowing, and heavy use can cause a vomiting syndrome that looks a lot like GLP-1 nausea. The most-cited research on the pairing, a 2024 study of health records, linked semaglutide to less cannabis use disorder, but it was observational and cannot prove the drug caused that.

Does weed cancel out a GLP-1's appetite suppression?

It can work against it, and the reason is well documented. THC is the active ingredient in dronabinol (Marinol), an FDA-approved prescription capsule. One of its two approved uses is "anorexia associated with weight loss" in people with AIDS, meaning it is prescribed specifically to make people hungry (Marinol prescribing information, DailyMed).

The same label says the appetite-stimulating effect "may continue for 24 hours or longer" after a dose, even though the psychoactive effects last about 4 to 6 hours. So the munchies may not end when the high does.

No published trial has measured how much THC blunts a GLP-1's effect on weight. The two push appetite in opposite directions, and how that plays out depends on how often you use, how much THC you take in, and what food is around.

Edibles on a slowed stomach: what is known and what isn't

Both major GLP-1 labels say the drugs delay gastric emptying. The Zepbound label states that the drug "delays gastric emptying and thereby has the potential to impact the absorption" of oral medicines taken at the same time (Zepbound prescribing information). The Wegovy label uses nearly identical language (Wegovy prescribing information).

Edibles depend on the gut. The CDC says edibles take from 30 minutes to 2 hours to produce intoxicating effects, and that the delay leads some people to take more, raising the risk of poisoning (CDC, Cannabis and Poisoning). For prescription oral THC, the dronabinol label lists onset at about 0.5 to 1 hour and peak effect at 2 to 4 hours.

What nobody has studied is how a GLP-1 changes those numbers. It is plausible that a slower stomach makes onset later or less predictable, which is exactly the setup for the "it isn't working, take another piece" mistake. But that is a reasonable inference, not a measured result. No trial or label quantifies it.

Smoked or vaped cannabis bypasses the stomach, so gastric emptying does not apply in the same way. That does not make it risk-free; the CDC notes smoked cannabis can harm lung tissue and that cannabis can raise heart rate and blood pressure right after use (CDC, Cannabis Health Effects).

Source: Marinol label, Zepbound label, Wegovy label, CDC.

GLP-1 nausea or cannabinoid hyperemesis? How to tell them apart

Nausea is the most common GLP-1 side effect. In the Wegovy weight-loss trials, 44% of people on the 2.4 mg dose reported nausea versus 16% on placebo, and 24% reported vomiting versus 6% (Wegovy prescribing information). On Zepbound, nausea ran 25% to 29% across doses versus 8% on placebo, and vomiting 8% to 13% versus 2% (Zepbound prescribing information).

Cannabinoid hyperemesis syndrome is a different problem. NIDA describes it as nausea, vomiting and abdominal pain after long-term, heavy cannabis use, which can recur and often needs medical attention. Hot showers or baths may bring temporary relief, but symptoms resolve only when the person stops using cannabis completely (NIDA, Cannabis (Marijuana)).

An emergency-medicine teaching summary from the University of Maryland lists the features clinicians look for: regular use at least weekly, compulsive hot-water bathing that eases symptoms, a workup that otherwise finds nothing, and complete relief within 7 to 10 days of stopping (UMEM Educational Pearls). It also notes the paradox that trips people up: many keep using because they believe cannabis helps nausea.

Source: NIDA, UMEM, Wegovy and Zepbound labels.

The two can overlap. A daily user who starts a GLP-1 and begins vomiting may have GLP-1 side effects, CHS, or both. The fixes differ, and using more cannabis to calm a GLP-1 stomach can backfire if CHS is part of the picture.

The cannabis use disorder study: what it found

The research behind the "Ozempic for weed" headlines is a retrospective cohort study by Wang and colleagues, with Nora Volkow of NIDA among the co-authors, published in Molecular Psychiatry in 2024 (Wang et al., Molecular Psychiatry 2024). It used electronic health records from the TriNetX network.

The researchers compared semaglutide with other weight-loss drugs (bupropion, naltrexone, orlistat, topiramate, phentermine) in people with obesity, and with other diabetes drugs in people with type 2 diabetes. They matched groups on many characteristics and followed them for 12 months.

Source: Wang W et al., Molecular Psychiatry 2024;29:2587-2598. CUD = cannabis use disorder.

For men specifically, the authors report that the reductions were consistent across gender and age groups, not confined to one subgroup. That is reassuring about generalizability, but it is still the same observational data.

Why this doesn't prove semaglutide treats cannabis use disorder

The authors list the limits themselves. It is an observational study, so it cannot show cause and effect. Unmeasured differences between people prescribed semaglutide and people prescribed other drugs could explain some of the gap. The records could not confirm that people took their medicine, and the study did not test dose effects. The authors describe the results as "preliminary evidence" and state that randomized clinical trials are needed before semaglutide could be used clinically for CUD.

Also keep the scale in mind. A new CUD diagnosis was rare in both groups, under half a percent over a year. For a man who already uses cannabis, the study says nothing about whether starting a GLP-1 will change his own habits.

For context on why researchers care: the CDC estimates that about 3 in 10 people who use cannabis have cannabis use disorder (CDC).

Before surgery, a colonoscopy or sedation: disclose both

This is the most concrete safety step on the list. The Wegovy and Zepbound labels both warn of rare reports of pulmonary aspiration in people on GLP-1 drugs during procedures with general anesthesia or deep sedation, including some who had food in the stomach despite fasting. Both labels tell prescribers to instruct patients to inform healthcare providers before any planned surgery or procedure (Wegovy label; Zepbound label).

Cannabis is its own anesthesia issue. The first US guidelines on perioperative cannabis, from the American Society of Regional Anesthesia and Pain Medicine in 2023, recommend that all patients having anesthesia be asked about cannabis, including product type, route, amount, frequency and time of last use. The ASRA summary also notes that regular users may have more pain and nausea after surgery, not less, and may need more pain medication (ASRA Pain Medicine, 2023).

The 2024 multi-society guidance on GLP-1s and surgery says most patients can keep taking their GLP-1 but that people at higher risk, such as those with active GI symptoms or in the dose-escalation phase, may need a liquid-only diet for 24 hours beforehand or other adjustments (American Society of Anesthesiologists, October 2024). Your anesthesia team can only plan for what they know about, so give them the full picture.

Questions to bring to your prescriber

• Given how often I use cannabis, how should we judge whether the GLP-1 is working?
• If I get nausea or vomiting, how do we sort out GLP-1 side effects from cannabinoid hyperemesis?
• Do I take other oral medicines whose absorption we should watch while my stomach is slowed?
• If I want to cut back on cannabis, what support is available? (The semaglutide data are not a treatment plan.)
• I have a procedure coming up. Who on the team needs to hear about the GLP-1 and the cannabis, and when?

Where this guide stops

This article does not give cannabis dosing guidance, and cannabis legality varies by state. Nothing here suggests using cannabis to manage GLP-1 nausea; the CHS evidence points the other way for regular users. If you are worried about your own use, NIDA and your primary care clinician are good starting points.

Key takeaway: Cannabis and GLP-1s are not a listed interaction, but THC's appetite push, the unknowns of edibles on a slowed stomach, and the overlap between CHS and GLP-1 nausea are real. Be honest with your prescriber and anesthesia team, and treat the cannabis use disorder data as promising but unproven.

Sources

1. Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations. Molecular Psychiatry 2024;29:2587-2598
2. Wegovy (semaglutide) prescribing information, Novo Nordisk, revised 06/2026
3. Zepbound (tirzepatide) prescribing information, Eli Lilly, revised 08/2026
4. Marinol (dronabinol) prescribing information, DailyMed
5. National Institute on Drug Abuse: Cannabis (Marijuana)
6. CDC: Cannabis Health Effects
7. CDC: Cannabis and Poisoning
8. University of Maryland Emergency Medicine Educational Pearls: Cannabinoid Hyperemesis Syndrome
9. ASRA Pain Medicine: All Patients Should Be Screened for Cannabis Use Before Surgery (2023)
10. American Society of Anesthesiologists: New Multi-society Clinical Practice Guidance Released (October 29, 2024)

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.